Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

DuPont Merck and Gilead Sciences are finalizing a program to make their new, experimental anti-HIV drugs available free to people who are not benefiting from other treatments. Enrollment information is included. The program includes the drugs DMP-266 and adefovir dipivoxil, and is a model for how drug companies can work together effectively to make experimental treatments available through expanded access programs. Initially, DMP-266 enrollment will be limited to 2,000 people with CD4 counts below 50 who are failing their current regimen. Adefovir will be available to 1,000 patients with CD4 counts below 50 and viral loads above 30,000. DMP-266 is a non-nucleoside reverse transcriptase inhibitor that is only taken once a day and shows great promise when used in combination with indinavir. Adefovir belongs to the nucleotide analog reverse transcriptase inhibitor class, and shows a unique resistance profile. It is also taken only once a day.
 ...
PMID:DMP-266 and adefovir dipivoxil: 2 new AIDS drugs available to patients without treatment options. 1136 9

DuPont Merck is opening an expanded access program for efavirenz (Sustiva), a non-nucleoside reverse transcriptase inhibitor (NNRTI). Efavirenz (formerly called DMP-266), the most potent NNRTI to date, is taken only once a day. To participate, patients must be failing therapy or be intolerant of current therapy. The patients are required to take the drug with another anti-HIV drug that they have never taken. Contact information for efavirenz studies, including a pediatric trial, is provided.
 ...
PMID:DMP 266 (Sustiva) expanded access. 1136 50

Although there have been great strides in AIDS research, there is no major development on the horizon that is capturing the attention of the press. However, there are significant developments being made in a number of areas. Current antiretroviral treatments are leading to declines in AIDS deaths and infections in the United States and studies are leading to a greater understanding of treatment failures and the role of compliance and adherence. Three new antiretrovirals are available in expanded access programs: abacavir (1592), efavirenz (Sustiva, DMP-266), and adefovir dipivoxil (Preveon, bis-POM PMEA). New treatment approaches will deal with restoring immune function, using vaccines to prevent HIV and opportunistic infection, and developing more antiretrovirals to combat the disease. The role of managed care and providing treatment to the uninsured and underinsured are also issues to be addressed in the coming year.
 ...
PMID:1998 outlook: treatment; research; access. 1136 51

As many as 25 to 45 percent of patients using triple therapy with protease inhibitors will develop resistance due to a change in the genetic HIV code. However, patients who develop resistance may still benefit clinically when protease inhibitors are used in combination with other antiretrovirals. These patients may not have undetectable viral loads although they may have stable T4-cell counts. Resistance does not always lead to disease progression. Newer drugs under development or available through compassionate track programs may benefit people with resistance. DMP-266 (Sustiva) is a non-nucleoside reverse transcriptase inhibitor that shows promise for these patients. Other drugs in development include Compound 141, 1592, and adefovir.
 ...
PMID:Understanding and managing resistance. 1136 97

Some of the latest developments in HIV treatment are described and contact information is given for people seeking further information on the topic. Clinical studies and preliminary results for interleukin-2 (IL-2), 1592U89 (abacavir), DMP-266 (efavirenz or Sustiva), and 141W94 (VX-94, Vertex) are described. Pharmaceutical companies are expected to continue developing new HIV drugs, including those in new drug classes, that will be more convenient, palatable, and less prone to resistance.
 ...
PMID:What's new and what's next. 1136 53

Anti-HIV therapy research continues to show promising results and a research update is presented on the following antiviral topics: efavirenz (DMP 266, Sustiva), indinavir (Crixivan), indinavir plus ritonavir (Norvir), hard vs. soft gel saquinavir, nelfinavir (Viracept) cross-resistance, and T-20 (pentafuside). Tables present regimen results, including viral load drop and CD4 cell increases. Difficulties in preventing viral resistance are also discussed. Situations to avoid include using dosing schedules that do not sufficiently suppress the virus, waiting for viral load to return to pre-treatment levels before switching drugs, and not switching drugs to at least two new potent compounds when changing combination therapy. The challenge for patients who have failed previous drug therapies is to develop strategies that allow them to extend the effectiveness of their options long enough for at least two new potent drugs to become available.
 ...
PMID:Update on antivirals. 1136 81

DuPont Merck, manufacturer of the experimental drug efavirenz (Sustiva, DMP-266), has issued a warning to researchers and physicians concerning birth defects found in 3 of 13 monkey fetuses whose mothers took the drug throughout gestation. Researchers believe that the abnormalities manifested in the early stages of pregnancy. Human trials require participants to use birth control, but now strongly emphasize not becoming pregnant while taking the drug. Efavirenz has not demonstrated harm in late pregnancy and may be used in future trials to block maternal/fetal transmission of HIV.
 ...
PMID:Notice on efavirenz and pregnancy. 1136 85

The Food and Drug Administration (FDA) approved DuPont Pharma's new non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva, DMP-266). Efavirenz has shown promise in trials with over 2000 participants for up to 24 weeks, and early data suggests it may be as effective as protease inhibitors when used in a combination regimen. It is the first anti-HIV drug approved for once-daily dosing. Efavirenz is well tolerated, and the main side effects reported are dizziness, insomnia, abnormal dreams, and skin rash. Efavirenz has been approved for adults and children, but should not be used by pregnant women. Contact information is provided.
 ...
PMID:FDA approves efavirenz. Food and Drug Administration. 1136 87

Information is provided on efavirenz (Sustiva, formerly DMP-266), including dosage information, resistance and clinical trial results, and pharmacology. Side effects are reviewed, as are interactions with other anti-HIV drugs. Contact information is provided.
Hopkins HIV Rep 1999 Jan
PMID:Product information. 1136 63

Updates are provided for new anti-HIV drugs currently in development. ABT-378, Tipranavir, and DMP-450 are among the new protease inhibitors discussed. Drugs from other classes that are discussed include emivirine (Coactinon, formerly MKC-442), FTC (emtricitabine, Coviracil), adefovir (Preveon), and pentafuside (T-20). A small study has found that women using Ritonavir (Norvir) may be at a greater risk for anemia (a decrease in red blood cells), caused by excessive menstrual bleeding or hypermenorrhea. New formulations of Ritonavir and ddI (Didanosine, Videx) are described.
 ...
PMID:New anti-HIV drugs in development. 1136 65


<< Previous 1 2 3 4 5 6 Next >>